2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelinesNCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Provenzale D, Gupta S, Ahnen D, Markowitz A, Chung D, Mayer R, Regenbogen S, Blanco A, Bray T, Cooper G, Early D, Ford J, Giardiello F, Grady W, Hall M, Halverson A, Hamilton S, Hampel H, Klapman J, Larson D, Lazenby A, Llor X, Lynch P, Mikkelson J, Ness R, Slavin T, Sugandha S, Weiss J, Dwyer M, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 939-949. PMID: 30099370, DOI: 10.6004/jnccn.2018.0067.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorColonoscopyColorectal NeoplasmsDNA, NeoplasmEarly Detection of CancerFecesHumansImmunochemistryMass ScreeningMedical OncologyMiddle AgedOccult BloodRandomized Controlled Trials as TopicSeptinsSocieties, MedicalTime FactorsTomography, X-Ray ComputedUnited StatesConceptsColorectal cancerNCCN GuidelinesRecommended screening strategySporadic colorectal cancerAverage-riskNCCN panelScreening modalitiesNCCN Guidelines InsightsScreening individualsIncreased-riskScreening strategiesNCCNGuidelinesRelevant dataIndividualsColorectalModalitiesPrimary focusScreeningRecommendationsReview commentsCancerFocus
2016
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly M, Pilarski R, Berry M, Buys S, Farmer M, Friedman S, Garber J, Kauff N, Khan S, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Merajver S, Offit K, Pal T, Reiser G, Shannon K, Swisher E, Vinayak S, Voian N, Weitzel J, Wick M, Wiesner G, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2016, 15: 9-20. PMID: 28040716, DOI: 10.6004/jnccn.2017.0003.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentOvarian cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesRisk of breastHereditary cancer syndromesPenetrant genetic mutationsMost recent recommendationsRelevant new dataPractice guidelinesCancer syndromesGenetic testingBreastSyndromeRecent recommendationsGenetic mutationsCancerManagement recommendationsRisk management recommendationsGuidelinesAssessmentPatientsRecommendations